When was Abbisko Therapeutics founded?

Abbisko Therapeutics was founded in 2016 and raised its 1st funding round 1 year after it was founded.

Where is Abbisko Therapeutics located?

Abbisko Therapeutics is headquartered in Shanghai, China.

Who is the current CEO of Abbisko Therapeutics?

Yao Chang Xu of Abbisko Therapeutics.

How many employees does Abbisko Therapeutics have?

As of Jul 01, 2024, the latest employee count at Abbisko Therapeutics is 51 - 200.

Is Abbisko Therapeutics a funded company?

Abbisko Therapeutics is a funded company, having raised a total of $263M across 4 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Feb 05, 2017.

When was the latest funding round of Abbisko Therapeutics?

Abbisko Therapeutics' latest funding was a $***** Series D round on Jan 08, 2021, with participation from 11 investors. Its primary sector is Diversified Pharmaceuticals. In China, the Diversified Pharmaceuticals sector has seen $68.7M in funding in 2026 to date.

Where does Abbisko Therapeutics rank among its competitors?

Abbisko Therapeutics ranks 8th amongst 60 active competitors, of which 17 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was Nura Bio, which secured $73.8M in Jun, 2026.

Who are the top competitors of Abbisko Therapeutics?

Abbisko Therapeutics' top competitors include Enliven Therapeutics, Rigel and BlossomHill Therapeutics. Among them, Nura Bio secured the most recent funding round in June, 2026.

Abbisko Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Company Details

Abbisko therapeutics is developing novel small molecule drugs for immunomodulatory pathways to treat cancer. The company's pipeline has three preclinical candidates. The exact mechanism of action of each moleule has not been disclosed but the company is possibly advancing a STING/TLR activator, IDO/CSF1R inhibitor and TGF agonist. The company's integrated R&D center locates in the Shanghai Zhangjiang Hi-Tech Park. The company claims to be surrounded by numerous top CRO, CMO and clinical contract organizations in the area, with whom they collaborate o research in drug discovery and development. In the future, the company aims to target other diseases such as liver disease, viral infections and mental disease

Key Metrics

Founded Year

2016

Location

Shanghai, China

Stage

Public

Total Funding

$263M in 4 rounds

Latest Funding Round

Series D, Jan 08, 2021, $*****

Investors

Temasek & 17 more

Ranked

8^th among 60 active competitors

Employee Count

51 - 200 as on Jul 01, 2024

Similar Companies

Enliven Therapeutics & 77 more

Exit Details

Public

View Abbisko Therapeutics' full profile

Abbisko Therapeutics got listed on Oct 13, 2021.

Click here to take a look at Abbisko Therapeutics's IPO in detail

Abbisko Therapeutics has raised a total funding of $263M over 4 rounds. Its first funding round was on Feb 05, 2017. Its latest funding round was a Series D round on Jan 08, 2021 for $*****. 11 investors participated in its latest round. Abbisko Therapeutics has 18 institutional investors.

Here is the list of recent funding rounds of Abbisko Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 08, 2021	8308020	Series D	1917885	2934669	5983911	2830434
Mar 25, 2020	7139335	Series C	2089183	3888387	4934742	Lilly Asia Ventures & 4 more
Mar 21, 2019	3291311	Series B	8392989	4082957	Qiming Venture Partners	CICC & 3 more

Access funding benchmarks and valuations. Sign up today!

View details of Abbisko Therapeutics's funding rounds and investors

Abbisko Therapeutics' employee count trend

Abbisko Therapeutics has 51 - 200 employees as of Jul 24. Here is Abbisko Therapeutics's employee count trend over the years:

Employee count trend for Abbisko Therapeutics

Uncover Abbisko Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Abbisko Therapeutics include Enliven Therapeutics, Rigel and BlossomHill Therapeutics. Here is the list of Top 10 competitors of Abbisko Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Enliven Therapeutics 2019, Boulder (United States), Public	Developer of drugs for solid tumours and blood cancers	$140M	Cormorant Asset Management, Surveyor Capital ... & 15 others	67/100
2nd	Rigel 1996, San Francisco (United States), Public	Developer of drugs for hematologic disorders, cancer, and rare immune disease	-	MPM Capital, MidCap Financial & 6 others	64/100
3rd	BlossomHill Therapeutics 2020, San Diego (United States), Series B	Developer of small molecule oncology therapeutics for treating cancer patients	$257M	Colt Ventures, Janus Henderson Investors & 8 others	63/100
4th	Q32 Bio 2018, Cambridge (United States), Public	Developer of drugs for treating autoimmune disorders	$106M	Atlas Venture, Orbimed & 9 others	63/100
5th	Nuvalent 2017, Cambridge (United States), Acquired	Developer of therapeutic solutions for the treatment of cancer	$185M	Bain Capital Life Sciences, Deerfield & 10 others	61/100
6th	NewAmsterdam Pharma 2019, Naarden (Netherlands), Public	Developer of transformative therapeutic solutions for cardio-metabolic diseases	$196M	Morningside, Forbion & 11 others	59/100
7th	Nura Bio 2018, San Francisco (United States), Series B	Provider of solution for diagnosis of a neurological disorder and neuroprotective medicines	$215M	The Column Group, Samsara BioCapital & 2 others	59/100
8th	Abbisko Therapeutics 2016, Shanghai (China), Public	Developing novel small molecule drugs for immunomodulatory pathways to treat cancer	$263M	GIC, Thecarlylegroup.fr & 16 others	59/100
9th	Sonnet BioTherapeutics 2011, Princeton (United States), Public	Developer of immunotherapies for the treatment of cancer	$750K	East West Capital Partners	57/100
10th	Kleo Pharmaceuticals 2015, New Haven (United States), Acquired	Developing a new class of immunotherapies utilizing small molecules to activate an individual's own immune system to fight against cancers and infectious diseases	$34.7M	PeptiDream, Biohaven Pharmaceutical & 2 others	53/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Abbisko Therapeutics's competitors? Click here to see the top ones

Abbisko Therapeutics has made no investments or acquisitions yet.

Media has covered Abbisko Therapeutics for a total of 14 events in the last 1 year, 4 of them have been about company updates and 4 about partnerships.